1. Scrip
  2. >>R&D

CellControl Biomedical Laboratories AG

 
• By Deborah Erickson

CellControl Biomedical Laboratories AG hopes oncologists will use its Chemoselect chemosensitivity test before deciding on a course of treatment for a cancer patient. The test can evaluate the effect of four to seven single substances or drug combinations on an individual's tumor cells. The firm is also working to develop cancer therapeutics--specifically an immune-stimulating vaccine against ovarian cancer.

"We want to see what the cells say," declares Nils Behnke, PhD, a member of the board of directors of CellControl Biomedical Laboratories AG . The company believes that the ChemoSelect chemosensitivity test it is currently developing will help oncologists determine the type of drug therapy most likely to be successful in any given patient. Instead of guessing which type of chemotoxic agent will be most effective at killing an individual's tumor cells, CellControl hopes doctors will use its diagnostic test to evaluate the effect of four to seven single substances or drug combinations—and only then select a treatment.

The technological roots of the ChemoSelect test reach back to drug-screening work that Rainer Metzger, PhD an academic scientist who...

Welcome to Scrip

Create an account to read this article

Already a subscriber?

More from R&D

AstraZeneca Faces Close Race With Mineralys After Phase III Hypertension Readout

 
• By Andrew McConaghie

There is little to divide the Phase III results for the two aldosterone synthase inhibitors, though AstraZeneca’s combination and cardiovascular outcomes studies could bear fruit in the long-term.

BeOne Preps For Sonrotoclax MCL Filing, With Sights Set On AbbVie/Roche’s Territory

 
• By Alaric DeArment

The biotech announced positive topline Phase I/II results for the BCL2 inhibitor in late-line mantle cell lymphoma, with Phase III studies underway in chronic lymphocytic leukemia.

J&J Keeps Faith In Nipocalimab’s $5bn Sales Target Despite RA Trial Setback

 
• By Manas Mishra

Johnson & Johnson will push ahead with its 'pipeline-in-a-product' plans for Imaavy despite pulling the plug on its development in rheumatoid arthritis.

DualityBio Eyes 1L Use For ADC Combos With BioNTech’s Bispecific

 
• By Dexter Jie Yan

Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.

More from Scrip

Executives On The Move: Legend Biotech Gets New CFO From AstraZeneca

Recent moves in the industry include an ex-Pfizer exec as the new CEO at Cha Vaccine Institute and a C-suite shuffle at Paragon Therapeutics, plus six other companies get new CFOs.

DualityBio Eyes 1L Use For ADC Combos With BioNTech’s Bispecific

 
• By Dexter Jie Yan

Duality is fast-tracking the development of three of its ADC candidates in combination with partner BioNTech's BNT327, an anti-PD-L1/VEGF-A bispecific antibody, in four studies, with certain cohorts evaluating first-line use in various cancers.

Lilly’s Verzenio Scores First OS Improvement In Key Breast Cancer Setting In Decades

 
• By Alaric DeArment

The drugmaker announced topline results for the CDK4/6 inhibitor in early HR-positive, HER2-negative breast cancer, giving it a competitive edge over Novartis’s Kisqali.